Biotechnology now stands where industry was more than a century
ago. Rapid growth only started after industrial processes could
be simulated mathematically. Before then progress was limited
by painfully slow empirical discovery (figure 1).
Medicinal
science is primarily based on empiricism. The current opportunities
for biotechnology can therefore be compared to the tremendous
opportunities that existed in 1900 for industrial development.
Over the past two decades we have focused on developing dynamic
simulation systems for complex energy processes and their control
(figure 2). This previous investment in engineering was
extended to human body simulation where much more value can be added.
The human body also consists of complex systems and controls. We
started our biotech R&D with the dynamic simulation of the human
energy (metabolic) system (figure 3). The first and critical
breakthrough discovery was the 
concept.
All interactions
in the complex human energy system (food, exercise, stress, counter
regulation and insulin control, etc.) can now be related to one
generic unit, .
This makes full dynamic system and control simulation possible
for the first time. Extensive clinical trials verified the accuracy
of the simulations. Very comprehensive literature searches (450
references) showed that the successful dynamic, fully integrated
simulation of the body’s energy (metabolic) system and its
full controls have not been achieved before.
Simulating
the human energy and control system means that levels of glucose,
tri-glyceride, fatty acid, etc. for any food intake, exercise,
stress, drugs, counter regulation control etc., or combination
thereof, can be established. It is then possible to develop better
methods, diagnostic tools, products and / or pharmaceuticals to
control these levels, but at a quicker pace and at a lower cost
than before. Simulation is thus the key to competitiveness.
After successful
computer simulation of the human carbohydrate metabolic cycle
was accomplished in 2002, clinical trials were carried out to
verify the predictions. Excellent results were found. Five diagnostic
products, aimed at the diabetic and bariatric (weight loss) markets,
were then developed based on the discoveries and insight gained.
All were patented.
We believe that based on our initial success with these preliminary
dynamic energy simulations we have potentially found the key to
accurately simulate other body systems and their controls. Our company's
technology vision is therefore to simulate, fully integrated and
dynamically, the full metabolic systems and their controls. Insight
gained through this simulation will lead to rapid development of
novel spin-off products for the healthcare market.
Our long-term
business objective is to establish a strong business through partnerships
using our lead in simulation as a competitive edge for biotechnology
and pharmaceutical product development.
Industry
Overview 
